MarketCapExport financials
Alterity Therapeutics Limited (ATHE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Alterity Therapeutics Limited Income Statement 2025-2011 | ATHE
Brief overview of income trends at Alterity Therapeutics Limited
This overview is based on financial performance over the past five years. Revenue at Alterity Therapeutics Limited moved from 364 thousand AUD in 2014 to 109 thousand AUD in 2019. The total change was −70.2%, with a CAGR of approximately −21.5%. Revenue ended the period on a sustained downward trend.
EBITDA changed from −19.8 million AUD to −17.3 million AUD (+12.8%). The operating result outpaced sales and points to improving efficiency. The EBITDA share of revenue changed from −5450% to −15926.5%. The margin contraction indicates weaker operating efficiency.
Comparing the endpoints shows a move from −13.3 million AUD to −12.3 million AUD. Losses became smaller, but the business remains unprofitable.
Market value was 96.7 million AUD at the start and 10.8 million AUD at the end. The financial trend was stronger than the market valuation.
What the figures show
The current trajectory does not yet confirm a sustainable recovery. Key strengths include net-income growth. The weaker side of the profile includes a declining EBITDA margin, a narrow EBITDA buffer and a weaker market valuation. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Alterity Therapeutics Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
29.4 B | 7.12 B | 6.6 B | 1.4 B | - | 895 M | 10.8 M | 18.8 M | 24.5 M | 40.9 M | 59.8 M | 96.7 M | 119 M | 44 M | 45.6 M |
Shares |
6.4 B | 3.65 B | 2.43 B | 2.41 B | 1.7 B | 895 M | 10.3 M | 8.89 M | 8.9 M | 8.9 M | 8.38 M | 7.13 M | 5.65 M | 4.8 M | 4.13 M |
Historical Prices |
4.6 | 1.95 | 2.72 | 0.58 | 0.85 | 1.6 | 0.6 | 1.61 | 2.67 | 2.19 | 3.6 | 6.66 | 67.9 | 12.7 | 10.7 |
Net Income |
-12.1 M | -19.1 M | -13.8 M | -12.8 M | -15.3 M | -13.5 M | -12.3 M | -8.27 M | -7.54 M | -7.73 M | -5.89 M | -13.3 M | -7.79 M | -5.24 M | -6.43 M |
Revenue |
- | - | - | - | - | - | 109 K | 201 K | 132 K | 143 K | 177 K | 364 K | 151 K | 2.53 M | 163 K |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | 177 K | 8.21 M | 4.49 M | 2.53 M | 163 K |
Interest Expense |
6.19 K | 7.22 K | 4.56 K | 2.28 K | 1.3 K | 3.88 K | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | - | - | - | - | -17.3 M | -10.9 M | -9.64 M | -13.1 M | -16.5 M | -19.8 M | -11.9 M | -5.29 M | -6.24 M |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | 16.7 M | 28.1 M | 16.4 M | 7.83 M | 6.44 M |
General and Administrative Expenses |
5.48 M | 4.76 M | 5.06 M | 5.51 M | 6.94 M | 3.45 M | 4.28 M | 4.32 M | 3.95 M | 3.59 M | 4.06 M | 3.09 M | 3.12 M | 3.46 M | 3.96 M |
Annual performance
Select metrics to display
All numbers in AUD currency
Quarterly Income Statement Alterity Therapeutics Limited
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | 6.4 B | - | 3.65 B | - | 2.43 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
- | -12.1 M | - | -19.1 M | - | -13.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | 6.19 K | - | 7.22 K | - | 4.56 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | 5.48 M | - | 4.76 M | - | 5.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in AUD currency
The income statement is one of the three key financial reports of a company Alterity Therapeutics Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
USA
Russia
Niderland
Israel
Britain
Irlanda
Singapore
